SCHEMBL3520296

SCHEMBL3520296

O=C(O)c1c(O)c(F)cc2nccnc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.37
DHODH Q02127 8/20 0.35
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
NAPRT Q6XQN6 1/20 0.33
KDM4E B2RXH2 5/20 0.33
ALDH1A1 P00352 3/20 0.33
ASPH Q12797 2/20 0.33
KDM8 Q8N371 2/20 0.33
PDE10A Q9Y233 1/20 0.32
LMNA P02545 2/20 0.31
MAPT P10636 2/20 0.31
TDP1 Q9NUW8 2/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
TP53 P04637 1/20 0.31
CA3 P07451 1/20 0.31
SELL P14151 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521209 0.79 EGLN3 (0.61) EGLN3
SCHEMBL3521085 0.79 DPP4 (0.44) EGLN3DHODHAKR1C2AKR1C1KDM4E
SCHEMBL3519604 0.79 KDM4E (0.45) EGLN3DHODHAKR1C2AKR1C1KDM4E
SCHEMBL3524401 0.79 EGLN3 (0.46) EGLN3DHODHPDE10ALMNA
SCHEMBL3567138 0.76 FABP3 (0.42) EGLN3ALDH1A1LMNACA1CA2
SCHEMBL3567141 0.73 PTPN1 (0.45) EGLN3
SCHEMBL3524985 0.71 EGLN3 (0.40) EGLN3KDM4EALDH1A1L3MBTL1
SCHEMBL3523631 0.71 EGLN3 (0.47) EGLN3DHODHNAPRTKDM4EALDH1A1
SCHEMBL3525718 0.70 EGLN3 (0.44) EGLN3DHODHKDM4EALDH1A1PDE10A
SCHEMBL3766998 0.69 CA12 (0.43) DHODHKDM4EALDH1A1PDE10ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885DHODH 20/4885AKR1C2 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.